Joseph Bollen

TL;DR: The findings provide a set of 11 relevant clinical variables associated with treatment resistance in major depressive disorder that can be explored at the clinical level and show that comorbid anxiety disorder is the most powerful clinical factor associated with TRD.

TL;DR: In depressed nonresponders to a previous antidepressant treatment, switching to a different class of antidepressants was not associated with a better response or remission rate and the evidence supporting the commonly suggested sequential use of antidepressants from 2 different pharmacological classes is weak.

TL;DR: The investigated cytochrome genes do not seem to play a major role in antidepressant response in the present sample of depressive patients, and methodological and sample size limitations of this study do not allow definitive conclusions.

TL;DR: The results preliminary suggest that some genetic polymorphisms in CREB1 could be associated to treatment resistance, and this finding increases current knowledge about the genetic predictors of response to antidepressants.

TL;DR: The study partially replicated the previous findings confirming a possible influence of COMT variants in MD and BD, particularly in early onset subjects, though not with the same risk genotypes.